Patents by Inventor Christiane Feron
Christiane Feron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160175423Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are characterized by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: March 2, 2016Publication date: June 23, 2016Inventors: Francois-Xavier Jacques BERTHET, Wilfried LJ DALEMANS, Philippe DENOEL, Joelle THONNARD, Christiane FERON, Jan POOLMAN, Georges THIRY, Pierre VOET, Yves LOBET, Guy DEQUESNE
-
Publication number: 20160082097Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: September 3, 2015Publication date: March 24, 2016Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20140294935Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: May 12, 2014Publication date: October 2, 2014Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, George Thiry, Joelle Thonnard, Pierre Voet
-
Patent number: 8221770Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: GrantFiled: October 21, 2010Date of Patent: July 17, 2012Assignee: GlaxoSmithKline Biologicals s.a.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20120064120Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20120064119Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20120027800Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: September 29, 2011Publication date: February 2, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Francois-Xavier Jacques Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20110033500Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: ApplicationFiled: October 21, 2010Publication date: February 10, 2011Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 7838014Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and Opc, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.Type: GrantFiled: July 31, 2003Date of Patent: November 23, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20100291137Abstract: The present invention provides an isolated refolded NspA protein, and a method of preparing it.Type: ApplicationFiled: January 25, 2010Publication date: November 18, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ralph Biemans, Martine Bos, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants, Johannes Petrus Maria Tommassen
-
Publication number: 20100285465Abstract: The present invention relates to a method of LOS molecular typing of a Neisseria strain by determining the presence of a functional gene and/or gene product of one or more genes involved in the biosynthesis of LOS.Type: ApplicationFiled: July 31, 2008Publication date: November 11, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Nathalie Isabelle Devos, Emmanuel Enrico Alexandre Di Paolo, Christiane Feron, Jan Poolman
-
Publication number: 20090246224Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects.Type: ApplicationFiled: June 8, 2007Publication date: October 1, 2009Inventors: Nathalie Devos, Christiane Feron, Jan Pollman, Vincent Weynants
-
Publication number: 20090123499Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects.Type: ApplicationFiled: June 8, 2007Publication date: May 14, 2009Inventors: Nathalie Devos, Christiane Feron, Jan Poolman, Vincent Weynants
-
Publication number: 20090117147Abstract: The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants.Type: ApplicationFiled: December 3, 2007Publication date: May 7, 2009Inventors: Francois-Xavier Jacques BERTHET, Wilfried L J. Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Nathalie Garcon, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20080233154Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: August 25, 2006Publication date: September 25, 2008Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20080025993Abstract: The present invention provides an isolated refolded NspA protein, and a method of preparing it.Type: ApplicationFiled: August 28, 2003Publication date: January 31, 2008Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20060240045Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.Type: ApplicationFiled: July 31, 2003Publication date: October 26, 2006Inventors: Francois-Xavier Berthet, Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Publication number: 20060216307Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: June 9, 2006Publication date: September 28, 2006Inventors: Francois-Xavier Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20060141563Abstract: An FrpB protein having one or more deletions of non-conserved amino acids compared to a corresponding wild-type FrpB protein, and a method of refolding an FrpB protein.Type: ApplicationFiled: August 28, 2003Publication date: June 29, 2006Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Karine Larine Goraj, Jeroen Kortekaas, Jan Poolman, Johannes Tommassen, Vincent Weynants
-
Publication number: 20060057160Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are less phase variable in terms of their LOS immunotype, and from which novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines can be derived.Type: ApplicationFiled: July 31, 2003Publication date: March 16, 2006Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Michael Jennings, Jan Poolman, Vincent Weynants